Developments in the clinical understanding of lupus

Advances in genetics and new understanding of the molecular pathways that mediate innate and adaptive immune system activation, along with renewed focus on the role of the complement system as a mediator of inflammation, have stimulated elaboration of a scheme that might explain key mechanisms in the pathogenesis of systemic lupus erythematosus. Clinical observations identifying important comorbidities in patients with lupus have been a recent focus of research linking immune mechanisms with clinical manifestations of disease. While these advances have identified rational and promising targets for therapy, so far the therapeutic trials of new biologic agents have not met their potential. Nonetheless, progress in understanding the underlying immunopathogenesis of lupus and its impact on clinical disease has accelerated the pace of clinical research to improve the outcomes of patients with systemic lupus erythematosus.

• Publication year

  2009

• Venue

  Arthritis Research & Therapy

• Publication date

  2009-10-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/ar2762PMID 19849817PMCID 2787273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

  2009cited by this paper
• Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

  2009cited by this paper
• Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus

  2009cited by this paper
• Age- and gender-specific modulation of serum osteopontin and interferon-α by osteopontin genotype in systemic lupus erythematosus

  2009cited by this paper
• Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

  2009cited by this paper
• Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies

  2009cited by this paper
• Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans.

  2009cited by this paper
• Anticytokine therapy impacting on B cells in autoimmune diseases

  2009cited by this paper
• Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells

  2009cited by this paper
• The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

  2009cited by this paper
• Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.

  2009cited by this paper
• Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN-α in Lupus Patients In Vivo1

  2009cited by this paper
• Association of the co-stimulator OX40L with systemic lupus erythematosus

  2009cited by this paper
• Cutting Edge: The PTPN22 Allelic Variant Associated with Autoimmunity Impairs B Cell Signaling1

  2009cited by this paper
• CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients.

  2009cited by this paper
• Copy number variation in the human genome and its implication in autoimmunity

  2009cited by this paper
• Systemic lupus erythematosus in the elderly: antimalarials in disease remission

  2009cited by this paper
• Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

  2009cited by this paper
• Genetic associations of LYN with systemic lupus erythematosus

  2009cited by this paper
• HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus

  2009cited by this paper
• Potent Induction of IFN-α and Chemokines by Autoantibodies in the Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus1

  2009cited by this paper
• Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications.

  2009cited by this paper
• Aberrant Epstein-Barr viral infection in systemic lupus erythematosus.

  2009cited by this paper
• Developments in the scientific understanding of lupus

  2008influential reference
• Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis.

  2008cited by this paper
• Trex1 prevents cell-intrinsic initiation of autoimmunity.

  2008cited by this paper
• Collaboration, genetic associations, and lupus erythematosus.

  2008cited by this paper
• A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases

  2008influential reference
• The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation

  2008cited by this paper
• Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci

  2008cited by this paper
• Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.

  2008cited by this paper
• Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.

  2008cited by this paper
• Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE

  2008cited by this paper
• A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.

  2008cited by this paper
• Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus

  2008cited by this paper
• Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.

  2008cited by this paper
• Linking retroelements to autoimmunity.

  2008cited by this paper
• Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

  2008cited by this paper
• The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.

  2008cited by this paper
• Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

  2008cited by this paper
• The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease.

  2008cited by this paper
• Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

  2008cited by this paper
• STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk

  2008cited by this paper
• High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

  2007cited by this paper
• High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus

  2007cited by this paper
• The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells.

  2007cited by this paper
• Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

  2007cited by this paper
• Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome.

  2007cited by this paper
• Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus.

  2007cited by this paper
• Faculty Opinions recommendation of Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis.

  2007cited by this paper
• Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus.

  2007cited by this paper
• Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

  2007cited by this paper
• HDL proteomics: pot of gold or Pandora's box?

  2007cited by this paper
• The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.

  2007cited by this paper
• Type I interferon in systemic lupus erythematosus.

  2007cited by this paper
• A Tlr7 translocation accelerates systemic autoimmunity in murine lupus.

  2006cited by this paper
• "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60.

  2006cited by this paper
• Discriminating Microbe from Self Suffers a Double Toll

  2006cited by this paper
• Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication

  2006cited by this paper
• Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors.

  2006cited by this paper
• Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.

  2006cited by this paper
• Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome

  2005cited by this paper
• Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome.

  2005cited by this paper
• Arterial Stiffness in Chronic Inflammatory Diseases

  2005cited by this paper
• Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

  2005cited by this paper
• Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

  2005cited by this paper
• Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

  2005cited by this paper
• Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

  2005cited by this paper
• Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus

  2004cited by this paper
• Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation

  2004cited by this paper
• B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

  2004cited by this paper
• Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.

  2004cited by this paper
• Costimulatory molecules and T-cell-B-cell interactions.

  2004cited by this paper
• Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

  2004cited by this paper
• Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.

  2004cited by this paper
• Interferon-alpha: a new target for therapy in systemic lupus erythematosus?

  2003cited by this paper
• Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

  2003cited by this paper
• Interferon-α: A new target for therapy in systemic lupus erythematosus?

  2003cited by this paper
• Powerful morphometric indicator of prognosis in lupus nephritis.

  2003cited by this paper
• Microarray Analysis of Interferon-regulated Genes in SLE

  2003cited by this paper
• Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

  2003cited by this paper
• Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

  2003cited by this paper
• Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

  2003cited by this paper
• Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study.

  2003cited by this paper
• Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

  2003cited by this paper
• T Cell Proliferation Induced by Autologous Non-T Cells Is a Response to Apoptotic Cells Processed by Dendritic Cells1

  2002cited by this paper
• Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss

  2002cited by this paper
• Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

  2001cited by this paper
• A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus

  2001cited by this paper
• A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus

  2001cited by this paper
• A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus

  2001cited by this paper
• Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

  2001cited by this paper
• Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus

  2001cited by this paper
• Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus.

  1999cited by this paper
• Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus.

  1999cited by this paper
• Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus.

  1998cited by this paper
• A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.

  1998cited by this paper
• A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus

  1998cited by this paper
• Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.

  1997cited by this paper
• Controlled trial with chloroquine diphosphate in systemic lupus erythematosus

  1996cited by this paper

• Dysregulated Intestinal Host–Microbe Interactions in Systemic Lupus Erythematosus: Insights from Patients and Mouse Models

  2025cites this paper
• A Study of IFN-α-Induced Chemokines CCL2, CXCL10 and CCL19 in Patients with Systemic Lupus Erythematosu

  2022cites this paper
• Therapeutic and clinical propositions of Mesenchymal Stem Cells(MSCs) focusing on recent trial updates

  2022cites this paper
• Transplant and Kidney Repair

  2020cites this paper
• Stem Cells in Urology

  2020cites this paper
• Overview and Clinical Presentation

  2019cites this paper
• IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.

  2019cites this paper
• Pulmonary Involvement in the Systemic Inflammatory Diseases of Childhood

  2019cites this paper
• Regulatory T cells in acute and chronic kidney diseases.

  2018cites this paper
• Connective Tissue Diseases

  2018cites this paper
• Mesenchymal stem cells: innovative therapeutic intervention for autoimmune rheumatic diseases

  2017cites this paper
• Mesenchymal Stem Cell Transplantation for Kidney Diseases

  2017cites this paper
• Systemic Lupus Erythematosus

  2016cites this paper
• Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence

  2016cites this paper
• Clinical Trials with Mesenchymal Stem Cells: An Update

  2016cites this paper
• Systemic lupus erythematosus

  2016cites this paper
• Human Umbilical Cord Mesenchymal Stem Cells Suppress Systemic Lupus Erythematosus Lesions by Rebalancing CD4+/CD8+ Cell Population

  2015cites this paper
• Complement-Targeted Therapies in Lupus

  2015cites this paper
• Efecto inmunomodulador de la administración de células troncales mesenquimales en pacientes con lupus eritematoso

  2014cites this paper
• Type I interferon signature in systemic lupus erythematosus.

  2014cites this paper
• Type I Interferon in the Pathogenesis of Lupus

  2014cites this paper
• t ype i interferon signature in s ystemic l upus erythematosus

  2014cites this paper
• Studies on Lupus Nephritis

  2013influential citation
• Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience

  2013cites this paper
• Nucleic Acid Sensors and Type I Interferon Production in Systemic Lupus Erythematosus

  2013cites this paper
• HLA-G 3′ Untranslated Region Polymorphisms Are Associated with Systemic Lupus Erythematosus in 2 Brazilian Populations

  2013influential citation
• Excess Female Siblings and Male Fetal Loss in Families with Systemic Lupus Erythematosus

  2013cites this paper
• Retinal and Choroidal Manifestations of Systemic Lupus Erythematosus (SLE)

  2013cites this paper
• Oral microbial colonization in patients with systemic lupus erythematous: correlation with treatment and disease activity

  2012cites this paper
• Níveis de interferon alfa e fator de necrose tumoal alfa em pacientes com lúpus eritematoso sistêmico juvenil : associações com manifestações clínicas

  2012cites this paper
• 274 – Systemic Lupus Erythematosus

  2012cites this paper
• 57 – Pulmonary Involvement in the Systemic Inflammatory Diseases of Childhood

  2012cites this paper
• Familial SLE: sustained drug-free remission in a mother successfully treated for anal cancer, but development of SLE in a 16-year old daughter

  2012cites this paper
• Role of Cytokines in Systemic Lupus Erythematosus: Recent Progress from GWAS and Sequencing

  2012cites this paper
• Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus

  2012cites this paper
• Association Study of ITGAM, ITGAX, and CD58 Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts

  2011cites this paper
• Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE.

  2011cites this paper
• Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus.

  2011cites this paper
• Systemic Sclerosis : Results from 2 Large European Caucasian Cohorts Autoimmune Risk Loci in CD 58 and ITGAM , ITGAX , Association Study of YANNICK ALLANORE

  2011cites this paper
• IRF-5 - A New Link to Autoimmune Diseases

  2011cites this paper
• Clinical epidemiology of Systemic Lupus Erythematosus with emphasis on nephritis and autoantibody production

  2011cites this paper
• A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients

  2011cites this paper
• Secondary Glomerular Disease

  2011cites this paper
• Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids.

  2010cites this paper
• Interferon-alpha: a therapeutic target in systemic lupus erythematosus.

  2010cites this paper
• Long interspersed nuclear elements (LINE-1): Potential triggers of systemic autoimmune disease

  2010cites this paper
• A Therapeutic Target in Systemic Lupus Erythematosus

  2010cites this paper
• Longevity of SLE-prone mice increased by dietary 2-mercaptoethanol via a mechanism imprinted within the first 28 days of life.

  2010cites this paper